- Home
- PRAX vs G Comparison
PRAX vs G Comparison
Compare PRAX & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | G |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.2B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PRAX | G |
|---|---|---|
| Price | $298.00 | $47.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $374.64 | $51.00 |
| AVG Volume (30 Days) | 586.2K | ★ 1.3M |
| Earning Date | 02-27-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.46% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.10 |
| Revenue | $7,463,000.00 | ★ $5,009,342,000.00 |
| Revenue This Year | N/A | $8.47 |
| Revenue Next Year | $14,827.76 | $6.90 |
| P/E Ratio | ★ N/A | $15.00 |
| Revenue Growth | ★ 364.98 | 7.39 |
| 52 Week Low | $26.70 | $37.49 |
| 52 Week High | $317.72 | $56.76 |
Technical Indicators
Market Signals| Indicator | PRAX | G |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 54.80 |
| Support Level | $266.93 | $46.35 |
| Resistance Level | $305.21 | $48.42 |
| Average True Range (ATR) | 15.96 | 0.87 |
| MACD | -3.30 | -0.19 |
| Stochastic Oscillator | 61.49 | 67.90 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About G Genpact Limited
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.